736 related articles for article (PubMed ID: 23180522)
1. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders.
Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M
Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522
[TBL] [Abstract][Full Text] [Related]
2. Transcatheter closure of patent foramen ovale associated with atrial septal aneurysm with Amplatzer Cribriform septal occluder.
Musto C; Cifarelli A; Pandolfi C; De Felice F; Fiorilli R; Caferri G; Violini R
J Invasive Cardiol; 2009 Jun; 21(6):290-3. PubMed ID: 19494408
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
[TBL] [Abstract][Full Text] [Related]
4. Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices - influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study.
Marchese N; Pacilli MA; Inchingolo V; Fanelli R; Loperfido F; Vigna C
EuroIntervention; 2013 Jul; 9(3):382-8. PubMed ID: 23872652
[TBL] [Abstract][Full Text] [Related]
5. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
6. Efficiency of transcatheter patent foramen ovale closure in children after paradoxical embolism events.
Wawrzyńczyk M; Gałeczka M; Karwot B; Knop M; Białkowski J
Kardiol Pol; 2016; 74(4):385-9. PubMed ID: 26412471
[TBL] [Abstract][Full Text] [Related]
7. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
Fischer D; Haentjes J; Klein G; Schieffer B; Drexler H; Meyer GP; Schaefer A
J Interv Cardiol; 2011 Feb; 24(1):85-91. PubMed ID: 20735710
[TBL] [Abstract][Full Text] [Related]
8. Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale.
Saguner AM; Wahl A; Praz F; de Marchi SF; Mattle HP; Cook S; Windecker S; Meier B
Catheter Cardiovasc Interv; 2011 Apr; 77(5):709-14. PubMed ID: 20931665
[TBL] [Abstract][Full Text] [Related]
9. Gore Helex septal occluder for percutaneous closure of patent foramen ovale associated with atrial septal aneurysm: short- and mid-term clinical and echocardiographic outcomes.
Musto C; Cifarelli A; Fiorilli R; De Felice F; Parma A; Pandolfi C; Confessore P; Bernardi L; Violini R
J Invasive Cardiol; 2012 Oct; 24(10):510-4. PubMed ID: 23043034
[TBL] [Abstract][Full Text] [Related]
10. Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale.
Susuri N; Obeid S; Ulmi M; Siontis GCM; Wahl A; Windecker S; Nietlispach F; Meier B; Praz F
EuroIntervention; 2017 Sep; 13(7):858-866. PubMed ID: 28437244
[TBL] [Abstract][Full Text] [Related]
11. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices.
Sorensen SG; Aguilar H; McKnight WK; Thomas H; Muhlestein JB
J Interv Cardiol; 2010 Dec; 23(6):575-80. PubMed ID: 20796165
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of patent foramen ovale closure for paradoxical emboli without echocardiographic guidance.
Varma C; Benson LN; Warr MR; Yeo E; Yip J; Jaigobin CS; Webb G; McLaughlin PR
Catheter Cardiovasc Interv; 2004 Aug; 62(4):519-25. PubMed ID: 15274165
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous transcatheter closure of high-risk patent foramen ovale in the elderly.
Takafuji H; Hosokawa S; Ogura R; Hiasa Y
Heart Vessels; 2019 Oct; 34(10):1657-1662. PubMed ID: 30868214
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism.
Cifarelli A; Musto C; Parma A; Pandolfi C; Pucci E; Fiorilli R; De Felice F; Nazzaro MS; Violini R
Int J Cardiol; 2010 Jun; 141(3):304-10. PubMed ID: 19178959
[TBL] [Abstract][Full Text] [Related]
15. A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION).
Puricel S; Arroyo D; Goy JJ; Praz F; Palhais N; Wahl A; Stauffer JC; Togni M; Berger A; Meier B; Cook S
EuroIntervention; 2015 Jun; 11(2):230-7. PubMed ID: 24830681
[TBL] [Abstract][Full Text] [Related]
16. The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.
Aral M; Mullen M
Catheter Cardiovasc Interv; 2015 May; 85(6):1058-65. PubMed ID: 25413379
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous patent foramen ovale closure: outcomes with the Premere and Amplatzer devices.
Bissessor N; Wong AW; Hourigan LA; Jayasinghe RS; Scalia GS; Burstow DJ; Griffiths LR; Savage M; Walters DL
Cardiovasc Revasc Med; 2011; 12(3):164-169. PubMed ID: 21640934
[TBL] [Abstract][Full Text] [Related]
18. Impact of occluder device type on success of percutaneous closure of atrial septal defects--a medium-term follow-up study.
Becker M; Frings D; Schröder J; Ocklenburg C; Mühler E; Hoffmann R; Franke A; Lepper W
J Interv Cardiol; 2009 Dec; 22(6):503-10. PubMed ID: 19821880
[TBL] [Abstract][Full Text] [Related]
19. Comparison of residual shunt rates in five devices used to treat patent foramen ovale.
Matsumura K; Gevorgyan R; Mangels D; Masoomi R; Mojadidi MK; Tobis J
Catheter Cardiovasc Interv; 2014 Sep; 84(3):455-63. PubMed ID: 24550064
[TBL] [Abstract][Full Text] [Related]
20. Transcatheter patent foramen ovale closure is effective in reducing migraine independently from specific interatrial septum anatomy and closure devices design.
Rigatelli G; Cardaioli P; Dell'Avvocata F; Giordan M; Braggion G; Chinaglia M; Roncon L
Cardiovasc Revasc Med; 2010; 11(1):29-33. PubMed ID: 20129358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
